Shaping the regulatory approach for generative AI‑enabled medical devices is something the US Food and Drug Administration (FDA) is seeking public feedback on after issuing a discussion paper.
The agency said it is requesting input on risk assessment, premarket evaluation, post-market monitoring, and other oversight considerations as generative AI